Sartorius AG

Sartorius AG

264.80
EUR
+2.00
(+0.76%)
Oct 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
792
891
1,115
1,300
1,405
1,566
1,827
2,336
3,449
4,175
3,396
3,381
3,538
- -
Operating Margin (%)
14.65
14.6
18.99
19.05
18.72
19.2
19.89
21.89
27.06
27.29
16.02
12.93
16.09
- -
Depreciation Expense
48
55
59
76
98
113
133
180
231
287
342
416
420
- -
Net Income, GAAP
52
48
126
103
115
141
157
210
319
678
206
84
155
- -
Effective Tax Rate (%)
30.71
33.65
31.9
28.96
20.81
27.05
27.85
29.47
36.12
22.73
24.85
26.45
31.6
- -
Profit Margin (%)
6.62
5.44
11.33
7.92
8.17
9.03
8.58
9
9.25
16.24
6.05
2.48
4.38
- -
Working Capital
146
187
206
223
278
273
188
338
250
220
627
669
-201
199
LT Debt
369
379
366
452
887
895
881
1,892
1,738
1,986
5,023
4,167
3,356
3,648
Total Equity
450
498
645
737
807
973
1,093
1,380
1,720
2,659
2,758
3,898
3,867
3,998
Return on Invested Capital (%)
9.24
9.05
13.6
12.82
11.47
11.31
11.27
10.96
11.41
20.56
6.22
3.29
4.37
- -
Return on Capital (%)
5.29
4.33
10.47
5.81
5.36
5.12
5.14
4.84
6.28
10.46
3.46
2.01
2.39
- -
Return on Common Equity (%)
14.94
12.67
27.59
18.76
19.16
20.81
20.21
22.81
27.83
41.73
10.13
3.48
5.66
- -

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
926
964
404
LT Borrowings
3,184
3,169
3,487
LT Finance Leases
172
168
162
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
- -
- -
- -

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,766
1,923
1,643
Cash, Cash Equivalents & STI
552
600
307
Accounts Receivable, Net
225
304
306
Inventories
792
827
832
Total Current Liabilities
1,967
2,113
1,445
Payables & Accruals
- -
- -
- -
ST Debt
926
964
404
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
20.65%
24.7%
-0.78%
Free Cash Flow
22.27%
11.45%
-30.23%
Net Income, GAAP
18.11%
24%
84.4%
Sales/Revenue/Turnover
13.49%
10.85%
4.66%
Total Cash Common Dividend
16.23%
28.58%
0.2%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
820
861
794
907
3,381
2025
883
884
- -
928
3,538
2026
899
912
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

CEO
Michael Grosse
Full Time Employees
14,042
Sector
Health technology
Industry
Medical specialties
Address
Otto-Brenner-Strasse 20 Goettingen NI Germany 37079
IPO Date
Apr 1, 1999
Business
Sartorius AG operates as a premier international supplier of laboratory equipment and bioprocess technology, headquartered in Göttingen, Germany, and serving the global life science research and biopharmaceutical sectors. The company empowers scientists and engineers through its comprehensive offerings, aimed at accelerating progress and simplifying complex workflows, ultimately enabling the development of advanced therapies and more accessible medicine. The organization is structured around two principal divisions: Bioprocess Solutions and Lab Products & Services. The Bioprocess Solutions segment delivers an extensive portfolio encompassing the entire biopharmaceutical production chain, from initial cell line development through to final purification and fluid management. This includes advanced biosensors, label-free detection platforms, and cell analysis systems, alongside a wide array of cell culture media and reagents for antibody, viral vaccine, regenerative medicine, and stem cell applications. Further, it provides multi-parallel, benchtop, single-use, and stainless steel bioreactors for cell culture and microbial fermentation, complete with associated software. The division also specializes in filtration products such as membranes, blotting media, syringe filters, and ultrafiltration and sterile filtration devices, in addition to advanced process chromatography solutions and comprehensive fluid management systems. The Lab Products & Services division furnishes research and quality control laboratories within pharmaceutical, biopharmaceutical, chemical, and food industries, as well as academic institutions, with essential instruments and consumables. Its offerings span high-precision laboratory balances, sophisticated pipetting and dispensing systems, and state-of-the-art laboratory water purification units. This segment also includes analytical tools like flow cytometry platforms and live-cell analysis systems, industrial microbiology solutions, and centrifuges. Beyond products, Sartorius offers critical services such as bioprocess development and engineering, biologics testing, and instrument validation. With a focus on single-use technologies and a razor/blade business model, the company generates significant recurring revenue through consumables, being "spec'd in" for regulatory approvals, which provides a long-term revenue stream for approved products. Recent strategic developments include a 2025 partnership with Tulip Interfaces to integrate automation solutions and the acquisition of MatTek, including Visikol Inc., to bolster capabilities in human cell-based microtissues for preclinical drug development. In 2024, Sartorius also entered a collaboration with Sanofi to commercialize a platform for integrated and continuous downstream bioprocessing. Founded in 1870, Sartorius maintains its global operations from its headquarters in Göttingen, Germany.

Company News

  • Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Stock Short Interest Rises 322.6%

  • Sartorius Aktiengesellschaft (SOAGY) Q2 2026 Earnings Call Transcript

  • Reviewing Integra LifeSciences (NASDAQ:IART) & Sartorius (OTCMKTS:SARTF)

  • Sartorius Aktiengesellschaft (SOAGY) Analyst/Investor Day Transcript

  • Sartorius Aktiengesellschaft (SOAGY) Q4 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (OTCMKTS:SOAGY) Short Interest Update

  • Critical Survey: ClearPoint Neuro (NASDAQ:CLPT) vs. Sartorius (OTCMKTS:SARTF)

  • Sartorius: Consistent Performance And Market Resurgence - Valuation Falls

  • 7 Stocks Taking The Next Step To Be On Offense

  • Sartorius Aktiengesellschaft (SOAGY) Q3 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q2 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q1 2025 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q4 2024 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q3 2024 Earnings Call Transcript

  • Sartorius Aktiengesellschaft (SARTF) Q1 2024 Earnings Call Transcript

  • SARTORIUS (SARTF) Upgraded to Strong Buy: Here's What You Should Know

  • Sartorius Aktiengesellschaft (SARTF) Q4 2023 Earnings Call Transcript

  • 10 stocks for investors looking for ‘wonderful companies at a fair price'

  • SARTORIUS (SARTF) Q3 Earnings Lag Estimates

  • Sartorius Aktiengesellschaft (SARTF) Q2 2023 Earnings Call Transcript